Suppr超能文献

经皮主动脉瓣置换术的进展和现状:CoreValve Revalving 系统三代器械的结果。

Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Revalving system.

机构信息

Departments of Cardiology, Cardiac Surgery, and Anaesthesiology, HELIOS Heart Center Siegburg, Ringstrasse 49, Siegburg, Germany.

出版信息

Circ Cardiovasc Interv. 2008 Dec;1(3):167-75. doi: 10.1161/CIRCINTERVENTIONS.108.819839.

Abstract

BACKGROUND

Percutaneous aortic valve replacement is a new emerging technology for interventional treatment of severe aortic valve stenosis in surgical high-risk patients. This study was intended to provide a summary of the development and current safety and efficacy status of the self-expanding CoreValve Revalving prosthesis.

METHOD AND RESULTS

Between 2005 and 2008, we have enrolled 136 consecutive patients with percutaneous aortic valve replacement using the CoreValve prosthesis. In this prospective nonrandomized, single-center trial, we analyzed procedural outcome, complications and clinical status up to 1 year. First, second, and third generation of the CoreValve prosthesis were implanted in 10, 24, and 102 consecutive high-risk patients (logistic EuroScore: 23.1+/-15.0%) with severe symptomatic aortic valve stenosis. Mean transvalvular pressure gradient was 41.5+/-16.7 mm Hg. The procedural success rate increased from generation 1/2 to 3 from 70.0%/70.8% to 91.2% (P=0.003). The 30-day combined rate of death/stroke/myocardial infarction was 40.0%/20.8%/14.7% (P=0.11) for generation 1, 2, and 3, with no procedural death in generation 3. Pressure gradients improved significantly with a final mean gradient of 8.1+/-3.8 mm Hg. Overall functional status assessed by New York Heart Association class improved from 3.3+/-0.5 (pre) to 1.7+/-0.7 (post) (P<0.001) and remained stable in the follow-up.

CONCLUSIONS

In experienced hands, percutaneous aortic valve replacement with the CoreValve system for selected patients with severe aortic valve stenosis has a high acute success rate associated with a low periprocedural mortality/stroke rate as well as remarkable clinical and hemodynamic improvements, which persist over time. Additional studies are now required to confirm these findings, particularly head-to-head comparisons with surgical valve replacement in different risk populations.

摘要

背景

经皮主动脉瓣置换术是一种新兴的介入治疗技术,适用于外科高危患者的严重主动脉瓣狭窄。本研究旨在总结自膨式 CoreValve Revalving 假体的发展现状和当前的安全性及疗效。

方法和结果

在 2005 年至 2008 年间,我们连续纳入了 136 例使用 CoreValve 假体行经皮主动脉瓣置换术的患者。在这项前瞻性、非随机、单中心试验中,我们分析了 1 年时的手术结果、并发症和临床情况。第一代、第二代和第三代 CoreValve 假体分别植入了 10、24 和 102 例连续的高危患者(Logistic EuroScore:23.1+/-15.0%),这些患者均患有严重症状性主动脉瓣狭窄。平均跨瓣压差为 41.5+/-16.7mmHg。手术成功率从第一代/第二代的 70.0%/70.8%增加到第三代的 91.2%(P=0.003)。第一代、第二代和第三代的 30 天死亡/卒中/心肌梗死联合发生率分别为 40.0%/20.8%/14.7%(P=0.11),第三代无手术死亡。压力梯度明显改善,最终平均梯度为 8.1+/-3.8mmHg。纽约心脏协会(NYHA)功能分级评估的整体功能状态从术前的 3.3+/-0.5 改善到术后的 1.7+/-0.7(P<0.001),且在随访期间保持稳定。

结论

在有经验的医生手中,对于特定的严重主动脉瓣狭窄患者,使用 CoreValve 系统行经皮主动脉瓣置换术具有较高的即刻成功率,围手术期死亡率/卒中率较低,临床和血液动力学改善显著,且随着时间的推移持续存在。现在需要进一步的研究来证实这些发现,特别是在不同风险人群中与外科瓣膜置换术进行头对头比较。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验